A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2012-12-01

Summary

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

• Phase: Phase 4

Details

• Lead Sponsor: Allergan
• Treatments: Alcaftadine; Dextrans; Olopatadine Hydrochloride